Study identifier:D9120C00025
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Single-blind, Randomized, Placebo-controlled, Single-centre Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetics after 7 Days Repeated Administration of Escalating Oral Doses of AZD3355 solution in Healthy Japanese Male Subjects
unknown
Phase 1
-
-
-
-
Interventional
-
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2013 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|